14 to go?, 13?, 12?…From Sept 3 release re: August stats .... "With 21 patients to full enrollment, the Company has entered the final push to fully enroll and finish the Tigris trial
- Based on current rate of enrollment, Tigris could be completed as early as December 2024
Dr. John Kellum, Chief Medical Officer of Spectral, noted, “It's gratifying to see that despite August vacation schedules, enrollment continues to be strong. We continue to enjoy very strong activity at our sites. As such, we remain confident in finalizing full Tigris enrollment around year end 2024.”
With the Sept stat release due this week, the home stretch is finally upon us.
And just in time for:
- Eden study results
- Baxter CG transaction closing on Vantive
- Prismax pump approval for use in HP across US
- CG's tire kicking review of Spectral? ( ie will they unveil a plan to be only in the competitive US dialysis business, or perhaps alternatively, a plan to be in the business of innovative precision medicine with a global reach, backed by multiple FDA approvals ?)
MM